Randomized Intergroup Trial of First Line Treatment for Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma With a CHOP-Like Chemotherapy Regimen With or Without the Anti-CD20 Antibody Rituximab (IDEC-C2B8).

Trial Profile

Randomized Intergroup Trial of First Line Treatment for Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma With a CHOP-Like Chemotherapy Regimen With or Without the Anti-CD20 Antibody Rituximab (IDEC-C2B8).

Completed
Phase of Trial: Phase III

Latest Information Update: 28 Mar 2016

At a glance

  • Drugs Rituximab (Primary) ; Bleomycin; Cyclophosphamide; Doxorubicin; Etoposide; Methotrexate; Mitoxantrone; Prednisolone; Prednisone; Vincristine
  • Indications Diffuse large B cell lymphoma
  • Focus Therapeutic Use
  • Acronyms MInT
  • Most Recent Events

    • 16 Apr 2010 Planned initiation date (Mar 2000) added as reported by Roche record.
    • 11 Aug 2009 Additional lead trial centre identified as reported by ClinicalTrials.gov.
    • 23 Mar 2008 Added sponsor and affiliate from Roche record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top